C - Chemistry – Metallurgy – 07 – K
Patent
C - Chemistry, Metallurgy
07
K
C07K 16/30 (2006.01) A61K 39/395 (2006.01) A61K 47/48 (2006.01) C12N 5/20 (2006.01) G01N 33/574 (2006.01) G01N 33/577 (2006.01) A61K 38/00 (2006.01)
Patent
CA 2286288
The present invention is related with the field of immunology and human medicine, particularly with the generation and selection of a monoclonal antibody (Mab) that recognizes the N-glycolylated-galactose-glucose sialic acid olygosaccharide sequence presents in malignant tumors. One of the objectives of this invention is to provide a Mab of the IgG1 type that has the characteristic of recognizing with high specificity N-glycolylated-galactose-glucose sialic acid olygosaccharide sequence presents in malignant tissues of breast , melanomas and tumors of the liver, stomach, colon, rectum and kidneys. It also has the capacity of producing direct cytolysis of the tumoral cells bearing the N- glycolylated-galactose-glucose sialic acid olygosaccharide sequence, thus can be used for the diagnosis and treatment of certain neoplasic diseases. Another objective of the present invention is to provide the hybridoma producing the referred Mab as well as the pharmaceutical composition containing it, for the treatment of neoplasic diseases.
L'invention concerne la branche de l'immunologie et de la médecine humaine, plus particulièrement la génération et la sélection d'un anticorps monoclonal (AcM) qui reconnaît l'oligosaccharide acide sialique N-glycolylé-galactose-glucose présent dans les tumeurs malignes. L'invention vise à apporter un AcM de type IgG1 susceptible de reconnaître avec forte spécificité la séquence d'oligosaccharide acide sialique N-glycolylé-galactose-glucose présente dans les tissus mammaires malins, ainsi que dans les mélanomes et tumeurs du foie, de l'estomac, du côlon, du rectum et du rein. L'AcM est aussi en mesure de provoquer une cytolyse directe des cellules tumorales porteuses de cette séquence d'oligosaccharide, ce qui permet son utilisation pour le diagnostic et le traitement de certaines néoplasies. L'invention vise en outre à fournir l'hybridome producteur de l'AcM mentionné, ainsi que la composition pharmaceutique le contenant, pour le traitement de néoplasies.
Carr Perez Adriana
Fernandez Molina Luis Enrique
Mazorra Herrera Zaima
Mulet Sierra Ailette
Perez Rodriguez Rolando
Centro de Inmunologia Molecular
Macrae & Co.
LandOfFree
Monoclonal antibody recognizing the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibody recognizing the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibody recognizing the... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1846721